PT - JOURNAL ARTICLE AU - Elke Wollants AU - Els Keyaerts AU - Lize Cuypers AU - Mandy Bloemen AU - Marijn Thijssen AU - Sien Ombelet AU - Joren Raymenants AU - Kurt Beuselinck AU - Lies Laenen AU - Lore Budts AU - Bram Pussig AU - Katrien Lagrou AU - Marc Van Ranst AU - Emmanuel André TI - Environmental circulation of adenovirus 40/41 and SARS-CoV-2 in the context of the emergence of acute hepatitis of unknown origin AID - 10.1101/2022.06.08.22276091 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.08.22276091 4099 - http://medrxiv.org/content/early/2022/06/09/2022.06.08.22276091.short 4100 - http://medrxiv.org/content/early/2022/06/09/2022.06.08.22276091.full AB - The recent surge of hepatitis of unknown origin in children is hypothesized to be caused by adenovirus 41 and/or SARS-CoV-2 infections. A relatively high proportion of patients testing positive for these viruses concomitantly with the development of acute hepatitis supports this hypothesis. To formally incriminate these viral infections as causative agents of hepatitis, both a plausible physiopathological pathway and supporting epidemiological dynamics in the community need demonstration. In this study, we measured the level of circulation of adenovirus 40/41 and SARS-CoV-2 in the general population of the city of Leuven in Belgium using wastewater monitoring between December 2020 and May 2022 and indoor air sampling in day care centers between November 2021 and May 2022. We also retrospectively analyzed medical records of 12.672 children attending a tertiary hospital draining the same region between January 2019 and April 2022. Our results demonstrate a recent but modest increase in hepatitis of unknown origin concomitant with a surge of circulating adenovirus 41 and SARS-CoV-2 in the general population, including in children under 5.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples of patients hospitalized in UZ Leuven, Belgium were used in this study according to the opting-out procedure of the hospital: https://www.uzleuven.be/en/consultation-and-admission/care/academic-research .This states that any bodily material remaining after a diagnostic examination or procedure (residual tissue) may be used for academic research, unless the patient objects to this use. As the Belgian National Reference Center the use of all patients residual and material together with consulting medical records which is only consulted by a licensed medical doctor, was approved by the University Hospital Ethics Committee, Leuven, Belgium. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors